Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Acuitive Technologies Inc. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed across 2 examiners and 2 art units, requiring separate attention to their examination contexts.
WELLES, COLMAN THOMAS is the busiest examiner, with 1 pending matter. The prosecution approach should preserve matter-specific arguments while keeping biotechnology terminology consistent where the disclosures overlap.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WELLES, COLMAN THOMAS | 1 | 26.9% | +65.7% |
| FUBARA, BLESSING M | 1 | 62.2% | +34.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18891944 | Charged Citrate-Based Biomaterials | WELLES, COLMAN THOMAS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18891944 | Charged Citrate-Based Biomaterials | WELLES, COLMAN THOMAS | — |
| 18397950 | Citrate-Based Constructs for Osteochondral Defect Repair | FUBARA, BLESSING M | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18891944 | Charged Citrate-Based Biomaterials | WELLES, COLMAN THOMAS | 1612 | §101§102§103§112DP | Non-Final OA | — | Pending | Sep 20, 2024 |
| 18397950 | Citrate-Based Constructs for Osteochondral Defect Repair | FUBARA, BLESSING M | 1613 | §102§103DP | Final Rejection | — | Pending | Dec 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAcuitive Technologies Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Colman Thomas Welles has the most, with 1 of Acuitive Technologies Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
